Long-term treatment of congestive heart failure with captopril.
1 The efficacy of the converting-enzyme inhibitor captopril in the management of severe congestive heart failure was assessed in 14 patients over 360-885 days by clinical evaluation, M-mode echocardiography, systolic time intervals, plasma renin activity, and plasma aldosterone. 2 As compared with baseline values, a significant reduction was observed in heart rate, mean arterial pressure, left ventricular end-diastolic and end-systolic diameters, left ventricular pre-ejection period, tension time index, body weight, and plasma aldosterone. Significant increases in left ventricular ejection time and fractional circumferential shortening (p less than 0.01) were also observed. 3 The functional and haemodynamic benefit provided by captopril was therefore sustained during long-term therapy without severe untoward effects or attenuation.
D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000097:blood; D002216:Captopril / Q000494:pharmacology / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011392:Proline / Q000031:analogs & derivatives*; D012083:Renin / Q000097:blood
D000450:Aldosterone; D011392:Proline; D002216:Captopril; D012083:Renin